Page last updated: 2024-12-07
bromofosfamide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
bromofosfamide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 128500 |
| CHEMBL ID | 78097 |
| SCHEMBL ID | 10783111 |
| MeSH ID | M0199421 |
Synonyms (23)
| Synonym |
|---|
| CHEMBL78097 |
| 2h-1,3,2-oxazaphosphorin-2-amine, n-(2-bromoethyl)-3-(2-chloroethyl)tetrahydro-, 2-oxide |
| km 135 |
| 2h-1,3,2-oxazaphosphorin-2-amine, n-(2-bromoethyl)-3-(2-chloroethyl)tetrahydro-, 2-oxide, (+-)- |
| 2h-1,3,2-oxazaphosphorin-2-amine, tetrahydro-n-(2-bromoethyl)-3-(2-chloroethyl)-, 2-oxide, (+-)- |
| brn 6768452 |
| tetrahydro-n-(2-bromoethyl)-3-(2-chloroethyl)-2h-1,3,2-oxazaphosphorin-2-amine 2-oxide |
| bromofosfamide |
| 2h-1,3,2-oxazaphosphorin-2-amine, tetrahydro-n-(2-bromoethyl)-3-(2-chloroethyl)-, 2-oxide |
| 146452-36-0 |
| 104149-14-6 |
| unii-j92cv4atfn |
| j92cv4atfn , |
| SCHEMBL10783111 |
| 2-[(2-bromoethyl)amino]-3-(2-chloroethyl)-1,3,2lambda5-oxazaphosphinan-2-one |
| AKOS033887619 |
| Z1269230176 |
| n-(2-bromoethyl)-3-(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine |
| 2-((2-bromoethyl)amino)-3-(2-chloroethyl)-1,3,2-oxazaphosphinane 2-oxide |
| Q27281361 |
| 2-[(2-bromoethyl)amino]-3-(2-chloroethyl)-1,3,2lambda~5~-oxazaphosphinan-2-one |
| DTXSID70908827 |
| EN300-260081 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "Three bromine-ifosfamide analogues: racemic chlorobromofosfamide (+/-)-(R,S)-1, its levorotatory enantiomer (-)-(S)-2 and racemic bromofosfamide (+/-)-(R,S)-3 showed considerable stereoselective differences in their pharmacokinetics and bioavailability depending on the route of administration and regimen of dosage studies in rats." | ( Pharmacokinetic-stereoselective differentiation of some isomeric analogues of ifosfamide. Hładoń, B; Kinas, R; Kuśnierczyk, H; Laskowska, H; Sloderbach, A; Sochacki, M, ) | 0.38 |
| " Its pharmacokinetics and bioavailability were studied in female mice following intravenous and oral administration of the dose of 50 mg/kg." | ( Pharmacokinetics of (-)-(S)-bromofosfamide after intravenous and oral administration in mice. Kobylińska, K; Kobylińska, M; Sobik, B, 2001) | 0.6 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "Three bromine-ifosfamide analogues: racemic chlorobromofosfamide (+/-)-(R,S)-1, its levorotatory enantiomer (-)-(S)-2 and racemic bromofosfamide (+/-)-(R,S)-3 showed considerable stereoselective differences in their pharmacokinetics and bioavailability depending on the route of administration and regimen of dosage studies in rats." | ( Pharmacokinetic-stereoselective differentiation of some isomeric analogues of ifosfamide. Hładoń, B; Kinas, R; Kuśnierczyk, H; Laskowska, H; Sloderbach, A; Sochacki, M, ) | 0.38 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (18)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID135975 | Number of mice that survived on day 60 at a dose of 80 mg/kg; 7/25 | 1988 | Journal of medicinal chemistry, Jan, Volume: 31, Issue:1 | Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group. |
| AID135974 | Number of mice that survived on day 60 at a dose of 60 mg/kg; 4/60 | 1988 | Journal of medicinal chemistry, Jan, Volume: 31, Issue:1 | Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group. |
| AID130311 | Percentage increase in life span of L1210 leukemia implanted mice at a dose of 200 mg/kg | 1988 | Journal of medicinal chemistry, Jan, Volume: 31, Issue:1 | Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group. |
| AID135956 | Number of mice that survived on day 60 at a dose of 200 mg/kg; 23/27 | 1988 | Journal of medicinal chemistry, Jan, Volume: 31, Issue:1 | Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group. |
| AID135971 | Number of mice that survived on day 60 at a dose of 50 mg/kg; 0/7 | 1988 | Journal of medicinal chemistry, Jan, Volume: 31, Issue:1 | Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group. |
| AID135940 | Number of mice that survived on day 60 at a dose of 100 mg/kg; 24/46 | 1988 | Journal of medicinal chemistry, Jan, Volume: 31, Issue:1 | Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group. |
| AID135960 | Number of mice that survived on day 60 at a dose of 300 mg/kg; 14/19 | 1988 | Journal of medicinal chemistry, Jan, Volume: 31, Issue:1 | Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group. |
| AID135947 | Number of mice that survived on day 60 at a dose of 150 mg/kg; 16/23 | 1988 | Journal of medicinal chemistry, Jan, Volume: 31, Issue:1 | Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group. |
| AID135968 | Number of mice that survived on day 60 at a dose of 400 mg/kg; 8/12 | 1988 | Journal of medicinal chemistry, Jan, Volume: 31, Issue:1 | Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group. |
| AID130315 | Percentage increase in life span of L1210 leukemia implanted mice at a dose of 400 mg/kg | 1988 | Journal of medicinal chemistry, Jan, Volume: 31, Issue:1 | Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group. |
| AID130306 | Percentage increase in life span of L1210 leukemia implanted mice at a dose of 120 50 mg/kg | 1988 | Journal of medicinal chemistry, Jan, Volume: 31, Issue:1 | Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group. |
| AID130309 | Percentage increase in life span of L1210 leukemia implanted mice at a dose of 150 mg/kg | 1988 | Journal of medicinal chemistry, Jan, Volume: 31, Issue:1 | Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group. |
| AID134723 | Lethal dose to kill 50% of the mice after single ip injection to healthy female CD2F1 mice | 1988 | Journal of medicinal chemistry, Jan, Volume: 31, Issue:1 | Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group. |
| AID130305 | Percentage increase in life span of L1210 leukemia implanted mice at a dose of 100 mg/kg | 1988 | Journal of medicinal chemistry, Jan, Volume: 31, Issue:1 | Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group. |
| AID132249 | Effective dose that causes 50% increase in life span of mice | 1988 | Journal of medicinal chemistry, Jan, Volume: 31, Issue:1 | Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group. |
| AID130319 | Percentage increase in life span of L1210 leukemia implanted mice at a dose of 60 mg/kg | 1988 | Journal of medicinal chemistry, Jan, Volume: 31, Issue:1 | Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group. |
| AID130320 | Percentage increase in life span of L1210 leukemia implanted mice at a dose of 80 mg/kg | 1988 | Journal of medicinal chemistry, Jan, Volume: 31, Issue:1 | Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group. |
| AID130314 | Percentage increase in life span of L1210 leukemia implanted mice at a dose of 300 mg/kg | 1988 | Journal of medicinal chemistry, Jan, Volume: 31, Issue:1 | Synthesis and antitumor activity of analogues of ifosfamide modified in the N-(2-chloroethyl) group. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.36
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.36) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (11.11%) | 5.53% |
| Reviews | 1 (11.11%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (77.78%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||